Keyword: Teva Pharmaceutical
So much for the forceful response Teva pledged after accusing Rimsa's former owners of fraud.
Teva will shutter its manufacturing facility in the Israeli port city of Ashdod by March 2019.
Just five months after Allergan’s CEO said the company wouldn’t break up, it’s reportedly weighing options for its women’s health unit.
California is starting to see early results from its new drug price transparency law, with red flags raised on two big hikes.
Prove it, GSK. So says a judge in the Coreg "carve-out" patent case that last year ended in a $235 million judgment against generics maker Teva.
Allergan took all kinds of criticism for its tribal licensing deal, but an appeals court decision has breathed new life into the strategy.
Endo, Teva and a Japanese drugmaker have agreed to fork over more than $270 million to resolve a class-action suit over Lidoderm.
In what may be the first foray by Big Pharma into the sale of medical marijuana products, Novartis has struck a deal with a Canadian company that sells medical cannabis products.
China FDA will take a new form; Celltrion's manufacturing issues might be worse than Teva hoped; Wuxi NextCODE and Google Cloud partner up.
Despite uncertainty heading into 2017, most drug stocks escaped the stagnation of 2016—some far more than others.